The company behind the juice “cleanse” brand Jus by Julie has been formally warned by the US Food and Drug Administration, or FDA, for medicinal claims that its says go well beyond those a food seller is allowed to make and, in a few cases, fraudulent claims about the products’ juice content.
In the April 5th warning letter to Jus Bar, LLC’s president, Sesar Melah, the FDA reveals that it spend 3 days at Jus’ facility last summer. Agents, at some point, also visited the company’s website, jusbyjulie.com. Based on information obtained by investigators the agency has deemed several of the company’s products “new drugs”.
A Juice With No Juice In It
Most of the claims Jus Bar was warned about concern medicinal claims but the company’s Almond Breeze Blended Juice, its Sweet Spin and its PB & Jus products were also singled out for calling themselves “blended juice” products because they were not pure juice.
In the case of the Almond Breeze drink there was actually no juice content whatsoever.
Depression, Hangover, Diabetes & Cancer Claims
Jus by Julie products are not, says the FDA, generally recognized as effective against medical conditions like diabetes, cancer or bacterial infections but 20 juice and soup products were either caught making such claims about their disease-fighting ability or making a similar claim about an ingredient in it.
The company’s Butternut Squash and its Creamy Carrot Ginger soups, for example, both made direct claims about their germ-fighting abilities. The Almond Breeze Blended Juice drink, on the other hand, is an example of a product hawking a particular ingredient. (In that case, the claim was made that the product’s cinnamon ingredient “controls inflammation in the body as well as protects you from cancer, bacterial infections and neurodegenerative diseases”.
The alleged violating claims covered medical conditions like:
- High cholesterol
- High blood pressure
- Bacterial and viral infections
As is normal with warning letters like these, Jus Bar was given the standard 15 working days to respond to the FDA’s allegations. As of my visit to the company’s website this morning, I did not find any of the claims the FDA mentioned in its letter.